This company has been marked as potentially delisted and may not be actively trading. NYSE:CHRO Chromocell Therapeutics (CHRO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock About Chromocell Therapeutics Stock (NYSE:CHRO) 30 days 90 days 365 days Advanced Chart Get CHRO alerts:Sign Up Key Stats Today's Range$1.23▼$1.4850-Day Range$1.34▼$13.5052-Week Range$4.50▼$38.00Volume194,032 shsAverage Volume47,337 shsMarket Capitalization$8.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Read More Receive CHRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRO Stock News HeadlinesChannel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private PlacementJune 27, 2025 | globenewswire.comChannel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing RulesMay 1, 2025 | globenewswire.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Ligand subsidiaries, Chromocell Therapeutics to mergeApril 17, 2025 | markets.businessinsider.comChannel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on SuzetrigineDecember 20, 2024 | globenewswire.comChannel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block ModelDecember 18, 2024 | globenewswire.comChromocell Therapeutics Corp (CHRO)December 13, 2024 | investing.comChannel Therapeutics Corporation (CHRO)December 5, 2024 | finance.yahoo.comSee More Headlines CHRO Stock Analysis - Frequently Asked Questions When did Chromocell Therapeutics' stock split? Chromocell Therapeutics's stock reverse split on the morning of Wednesday, July 2nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Chromocell Therapeutics IPO? Chromocell Therapeutics (CHRO) raised $7 million in an IPO on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share. Company Calendar Today8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:CHRO Previous SymbolNYSE:CHRO CIK1919246 Webchromocell.com Phone732-514-2636FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.38 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-453.90% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.65) per share Price / Book-0.81Miscellaneous Outstanding Shares6,485,000Free Float5,039,000Market Cap$8.69 million OptionableN/A Beta3.63 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NYSE:CHRO) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.